Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $27.3 million, with total revenue for the first nine months of 2022 at $143 million, primarily from royalty revenue related to partnerships with Vir and Alexion [16][18] - Total cash, cash equivalents, receivables, and marketable debt securities at September 30 totaled $564.6 million, down from $664.1 million at the beginning of the year, with an updated year-end cash position guidance of $575 million to $600 million [17][18] Business Line Data and Key Metrics Changes - XmAb564, a reduced potency cytokine targeting regulatory T-cells, showed promising biomarker data in a Phase 1 single-dose study, indicating well-tolerated subcutaneous administration and significant Treg expansion [10][23] - Vudalimab, a Phase 2 PD-1 by CTLA-4 dual checkpoint bispecific antibody, is enrolling patients for studies in metastatic castration-resistant prostate cancer and advanced gynecologic tumors [11][12] Market Data and Key Metrics Changes - The company is focusing on autoimmune diseases and oncology, leveraging its modular protein engineering tools to create a diverse development portfolio [9][10] - The Phase 1a study of XmAb564 demonstrated a significant increase in CD25 bright Treg counts, with a peak of about 150 cells per microliter at the highest dose [40] Company Strategy and Development Direction - The company aims to use proof-of-concept data from early-stage studies to guide the advancement, termination, or partnering of programs, focusing resources on those with the greatest potential for success [10] - XmAb564 is positioned as a potential best-in-class treatment in autoimmune diseases, with plans to explore multiweek dosing schedules in ongoing studies [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of XmAb564 and its ability to provide durable Treg expansion, which could lead to improved therapeutic profiles in autoimmune diseases [50][51] - The company is committed to advancing its pipeline quickly while monitoring biomarker data to inform dosing strategies [65][66] Other Important Information - The company has sufficient cash and equivalents to fund R&D programs and operations through the end of 2025 [18] - XmAb564 is the second clinical program in the XmAb cytokine platform, with plans for additional programs to follow [52][53] Q&A Session Summary Question: Duration of dosing for atopic dermatitis and psoriasis patients - Management indicated that patients will be dosed for eight weeks, primarily focusing on biomarker data [59][60] Question: Comparison of XmAb564 with other drugs in development - Management highlighted that XmAb564's half-life and Treg expansion metrics are competitive compared to other therapies, suggesting a strong position in the market [70] Question: Insights on anti-drug antibodies - No evidence of anti-drug antibodies was observed in the early analysis of XmAb564 [107] Question: Recruitment for plamotamab combination trials - Recruitment for plamotamab is ongoing, with studies expanding beyond the U.S. [68] Question: Variability in Treg expansion data - Management expressed confidence in the data despite variability due to small sample sizes, emphasizing consistent trends across multiple measures [119][120]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-1 ...

| --- | --- | --- | --- | --- | |--------------------|-------|-------|-------|-------| | | | | | | | Proteins by Design | | ® | | | Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2022 was $31 million, and for the first six months, it was $115.6 million, primarily from royalty revenue related to partnerships with Vir and Alexion [20][21] - Total cash equivalents, receivables, and marketable debt securities at June 30, 2022, totaled $679.7 million, an increase of approximately $50 million from the beginning of the year [21][22] - The company updated its year-end guidance, estimating a cash balance between $550 million and $575 million by the end of 2022, sufficient to fund R&D programs through the end of 2025 [22] Business Line Data and Key Metrics Changes - The company has three royalty-producing marketed products, including ULTOMIRIS, which received a positive opinion from CHMP in Europe for generalized myasthenia gravis [8] - The company is advancing multiple clinical programs, including XmAb-564, plamotamab, and vudalimab, with data presentations planned through the end of the year [12][13][14] Market Data and Key Metrics Changes - The company is exploring external collaborations to enhance its technology for creating new drug molecules, exemplified by a partnership with Caris Life Sciences for target discovery [9] - The competitive landscape includes other companies like Amgen, which is advancing similar bispecific programs [18] Company Strategy and Development Direction - The company aims to utilize proof-of-concept data from early-stage studies to guide its development portfolio, focusing on programs with the greatest potential for success [6][7] - The modular approach and engineering tools allow the company to create a broad internal development portfolio in oncology and autoimmune diseases [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to avoid accessing public markets for capital for over four years due to revenue from strategic licensing and collaboration agreements [7] - The management highlighted the importance of differentiating their IL-15 assets from competitors, emphasizing a systemic therapy approach compared to local delivery methods [36][38] Other Important Information - The company is initiating a Phase I study of XmAb808, a CD28 targeting bispecific antibody, in combination with pembrolizumab [19] - The company is also exploring various immune indications for its IL-2 Fc program, with plans to disclose initial indications in the coming months [41] Q&A Session Summary Question: Can you talk about the B7-H3 target and its competitive landscape? - Management indicated that B7-H3 is a broadly expressed target across various solid tumor histologies and expressed no immediate concerns regarding recent adverse events reported by competitors [27][28] Question: What are the differentiating factors for your IL-15 assets compared to competitors? - The company highlighted that their IL-15 program is designed for systemic therapy, contrasting with a competitor's local delivery method, which may limit broader application [36][38] Question: How do you view the upcoming data readout for vudalimab? - Management noted that the initial data readout would be too early to draw conclusions about different patient subtypes but would provide insights into efficacy and tolerability [63] Question: What drove the increase in guidance for cash balance at year-end? - The increase was primarily attributed to higher-than-expected royalty revenue from partnerships, which provided more clarity on timing and amounts [108][109]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-162250 ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Jonathan Chang - SVB Securities Supawat Thongthip - Mizuho Dane Leone - Raymond James Charles Zhu - Guggenheim Securities Etzer Darout - BMO ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-16225 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of I ...

Xencor, Inc. (NASDAQ:XNCR) Q4 2021 Earnings Conference Call February 22, 2022 5:00 PM ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications & IR Bassil Dahiyat - Co-Founder, CEO, President & Director Allen Yang - SVP & Chief Medical Officer John Kuch - SVP & CFO John Desjarlais - SVP, Research & Chief Scientific Officer Conference Call Participants Jonathan Chang - SVB Leerink Kaveri Pohlman - BTIG Mara Goldstein - Mizuho Securities Charles Zhu - Guggenheim Arlinda Le ...

Xencor, Inc. (NASDAQ:XNCR) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants Charles Liles – Head-Corporate Communications and Investor Relations Bassil Dahiyat – President and Chief Executive Officer Allen Yang – Chief Medical Officer John Desjarlais – Chief Scientific Officer John Kuch – Chief Financial Officer Conference Call Participants Ted Tenthoff – Piper Sandler Mara Goldstein – Mizuho David Nierengarten – Wedbush Securities Kaveri Pohlman – BTIG Charles Zhu – Guggenh ...